MedTrace Logo

PROPULSION SANTE: Inflammometry to Improve the Diagnostic Trajectory in Situations of Suspected Asthma in Children and Adults

NCT06981169 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2026-04-30

No results posted yet for this study

Summary

The objective of this observational study is to assess the relevance of inflammometry (based on the measurement of fractional exhaled nitric oxide (FeNO) and blood eosinophil count (BEC)) as a tool for prioritizing respiratory diagnostic tests.

The study will evaluate the role of inflammometry (FeNO and BEC) in prioritizing diagnostic respiratory tests. It will include patients aged six and older with suspected asthma, referred by non-pulmonologists for diagnostic asthma testing (spirometry or methacholine challenge test) at three hospital centers: Sherbrooke University Hospital Center (CHUS), Sainte-Justine University Hospital Center (CHU Sainte-Justine), and the Montreal Children's Hospital.

The hypothesis is that using inflammometry as a prioritization tool would reduce diagnostic delays for high-risk patients with elevated biomarkers. This study could help shorten wait times, relieve congestion in diagnostic testing queues, and improve the diagnostic pathway. Additionally, it would enhance the interpretation of pulmonary function test results by incorporating inflammometry findings, leading to better patient stratification.

Patients referred from primary care will undergo pulmonary function testing (spirometry ± methacholine challenge) and, as part of the study:

FeNO measurement using a portable device Blood test for eosinophil count Questionnaire on asthma control and quality of life, completed at the visit and at follow-ups at 4, 8, and 12 months

Conditions

Interventions

DIAGNOSTIC_TEST

FeNO

FeNO measured with a NIOX VERO device before the respiratory test

DIAGNOSTIC_TEST

blood sample

Blood sample for measuring the blood eosinophil count

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Niox Group Plc

    collaborator UNKNOWN

  • Ministere de la Sante et des Services Sociaux

    collaborator OTHER

  • Association Pulmonaire du Quebec

    collaborator OTHER

  • Fonds recherche du Québec Santé

    collaborator UNKNOWN

  • Université de Sherbrooke

    lead OTHER

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-24
Primary Completion
2026-12-01
Completion
2027-07-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06981169 on ClinicalTrials.gov